Vertex forecasts upbeat 2025 revenue on cystic fibrosis treatments demand
Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...
Vertex Pharmaceuticals' Revenue Forecast Tops Expectations
Vertex Pharmaceuticals (VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ ...
Vertex Pharmaceuticals (VRTX) Q4 2024 Earnings Call Transcript
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.C79yHELW.js ...
Vertex's Revenue Surges but EPS Slips
The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.
BioSpace5h
Vertex Eyes Expansive, Easy Access for Journavx in Coming Weeks
Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...
STAT4h
Vertex pain pill dominates earnings call discussion
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Vertex: Strong Sales, Stronger Pipeline
One of the most significant news items involving Vertex isn't reflected in the company's numbers just yet. Vertex's non-opioid pain relief drug, Journavx, received FDA approval on Jan. 30. The drug is ...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...
Stocktwits on MSN5h
Vertex Pharma Stock Flooded With Price-Target Hikes After Upbeat Q4 Revenue, 2025 Outlook: Retail Stays Bullish
Shares of Vertex Pharmaceuticals, Inc. were in the spotlight in premarket trading Tuesday as the biotech company received ...